Your healthcare provider may continue increasing the dose every four weeks based on your response and tolerance
The sequential process of participant recruitment, intervention titration, and longitudinal follow-up is illustrated in Figure 1
SURMOUNT-OSA: Tirzepatide and obstructive sleep apnea The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024, NEJMoa2404881, PMID 38912654) evaluated tirzepatide in adults with moderate to severe obstructive sleep apnea and obesity, in two parallel populations: subjects not receiving continuous positive airway pressure (CPAP) and subjects receiving CPAP at baseline
[6] [7] [10] GPx1 typically uses glutathione (GSH) as the reductant, but when glutathione synthetase (GSS) is, as in brain mitochondria, -glutamylcysteine can serve as the reductant instead
You were denied coverage Appeal the denial over 65% succeed